Published in:
01-05-2016 | Erratum
Erratum to: Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy
Published in: Journal of Gastroenterology | Issue 5/2016
Login to get accessExcerpt
In Table 2, clerical mistakes of the number of patients in low or high than 15.0 ng/ml were made. The number of patients with low than 15.0 ng/ml should be 40, and high should be 25. Table 2 should be shown as follows.
Table 2
Correlation between basic HER2 ECD status response rates for AGC patients treated with trastuzumab
|
Baseline serum HER2 ECD
|
||||
|---|---|---|---|---|
|
Parameter
|
Low (n = 40) (<15.0 ng/ml)
|
High (n = 25) (≥15.0 ng/ml)
|
Low (n = 18) (<10.65 ng/ml)
|
High (n = 47) (≥10.65 ng/ml)
|
|
Respond rate
|
50.00
|
80.00
|
28.57
|
72.34
|
|
95 % CI
|
37.45–62.54
|
69.96–90.04
|
17.23–39.91
|
61.13–83.55
|
|
Odds ratio
|
4.000
|
6.538
|
||
|
95 % CI
|
1.232–12.898
|
1.740–24.574
|
||
|
P value
|
0.017
|
0.003
|
||